Your session is about to expire
← Back to Search
Intraocular Lens
Phacoemulsification surgery for Cataract
N/A
Waitlist Available
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 3 postoperative visit
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing new lenses used in cataract surgery to help people see better. It involves adults who have cataracts in both eyes. The new lenses replace the cloudy ones removed during surgery, helping patients see clearly again.
Eligible Conditions
- Cataract
- Pseudoaphakia
- Aphakia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ month 3 postoperative visit
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 3 postoperative visit
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Binocular Best-corrected Distance Visual Acuity (BCDVA) at 4 Meters Under Bright Lighting Conditions
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Clareon/Clareon ToricExperimental Treatment3 Interventions
Phacoemulsification surgery, followed by implantation with Alcon Clareon Aspheric Hydrophobic Acrylic IOL or Alcon Clareon Aspheric Hydrophobic Acrylic Toric IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
Group II: Eyhance/Eyhance ToricActive Control3 Interventions
Phacoemulsification surgery, followed by implantation with TECNIS Eyhance IOL or TECNIS Eyhance Toric II IOL, as indicated. The second eye surgery is recommended to occur within 14 days after the 1st eye surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clareon Toric IOL
2022
N/A
~210
Clareon IOL
2022
N/A
~210
Phacoemulsification surgery
2013
N/A
~270
Find a Location
Who is running the clinical trial?
Alcon ResearchLead Sponsor
731 Previous Clinical Trials
128,706 Total Patients Enrolled
118 Trials studying Cataract
20,791 Patients Enrolled for Cataract
Clinical Trial Lead, CDMA SurgicalStudy DirectorAlcon Research, LLC
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I'm sorry, could you please provide more context or information about the term "Key"?You have any eye condition, except cataracts, that could make your vision worse than a certain level.There may be additional requirements for participation in the study that are specific to the protocol.You need to have a specific range of corneal astigmatism to be eligible for the study.You have eye problems like damaged cornea, dry eyes, or diseases affecting the surface of your eyes that could affect the accuracy of measurements and calculations for vision correction.
Research Study Groups:
This trial has the following groups:- Group 1: Clareon/Clareon Toric
- Group 2: Eyhance/Eyhance Toric
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger